News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica, Inc. (NASDAQ: CALC) had its price target lowered by analysts at HC Wainwright from $20.00 to $16.00. They now have a "buy" rating on the stock.

CalciMedica Announces Pricing of Public Offering of Common Stock

Form SC 13G/A CalciMedica, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Form SC 13G/A CalciMedica, Inc. Filed by: LYTTON LAURENCE W

Form SC 13G/A CalciMedica, Inc. Filed by: Stonepine Capital Management, LLC

Form 10-Q CalciMedica, Inc. For: Sep 30

Form 8-K CalciMedica, Inc. For: Nov 13

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}